BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025

Reuters12-08

BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025

BeOne Medicines AG has announced new clinical data on sonrotoclax, a next-generation investigational BCL2 inhibitor, at the 67th American Society of Hematology $(ASH)$ Annual Meeting & Exposition. The results demonstrate that sonrotoclax monotherapy achieved deep and durable clinical responses in patients with relapsed or refractory mantle cell lymphoma (R/R MCL) and chronic lymphocytic leukemia (R/R CLL). In combination with BRUKINSA, sonrotoclax showed rapid achievement of minimal residual disease (MRD) negativity in treatment-naive CLL, regardless of high-risk features. The overall response rate for sonrotoclax in R/R MCL was reported at 52.4%, and the best undetectable MRD rate in blood was 49.0%. Sonrotoclax monotherapy was generally well tolerated with manageable toxicities and no clinical tumor lysis syndrome observed. Updated data are scheduled to be presented on December 8, and the results are under review by China's National Medical Products Administration for potential accelerated approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251207830814) on December 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589809499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 07:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589809499","market":"fut","top_or_hot":-1,"title":"BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeOne Medicines AG has announced new clinical data on sonrotoclax, a next-generation investigational BCL2 inhibitor, at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting &amp; Exposition. The results demonstrate that sonrotoclax monotherapy achieved deep and durable clinical responses in patients with relapsed or refractory mantle cell lymphoma (R/R MCL) and chronic lymphocytic leukemia (R/R CLL). In combination with BRUKINSA, sonrotoclax showed rapid achievement of minimal residual disease (MRD) negativity in treatment-naive CLL, regardless of high-risk features. The overall response rate for sonrotoclax in R/R MCL was reported at 52.4%, and the best undetectable MRD rate in blood was 49.0%. Sonrotoclax monotherapy was generally well tolerated with manageable toxicities and no clinical tumor lysis syndrome observed. Updated data are scheduled to be presented on December 8, and the results are under review by China's National Medical Products Administration for potential accelerated approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251207830814) on December 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 07:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeOne Medicines AG has announced new clinical data on sonrotoclax, a next-generation investigational BCL2 inhibitor, at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting &amp; Exposition. The results demonstrate that sonrotoclax monotherapy achieved deep and durable clinical responses in patients with relapsed or refractory mantle cell lymphoma (R/R MCL) and chronic lymphocytic leukemia (R/R CLL). In combination with BRUKINSA, sonrotoclax showed rapid achievement of minimal residual disease (MRD) negativity in treatment-naive CLL, regardless of high-risk features. The overall response rate for sonrotoclax in R/R MCL was reported at 52.4%, and the best undetectable MRD rate in blood was 49.0%. Sonrotoclax monotherapy was generally well tolerated with manageable toxicities and no clinical tumor lysis syndrome observed. Updated data are scheduled to be presented on December 8, and the results are under review by China's National Medical Products Administration for potential accelerated approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251207830814) on December 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688235","symbol_name":"百济神州","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9G7LkX:1","article_id":"2589809499","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589809499","pubTimestamp":1765148420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BeOne Medicines AG has announced new clinical data on sonrotoclax, a next-generation investigational BCL2 inhibitor, at the 67th American Society of Hematology  Annual Meeting & Exposition. The results demonstrate that sonrotoclax monotherapy achieved deep and durable clinical responses in patients with relapsed or refractory mantle cell lymphoma  and chronic lymphocytic leukemia . In combination with BRUKINSA, sonrotoclax showed rapid achievement of minimal residual disease  negativity in treatment-naive CLL, regardless of high-risk features. The overall response rate for sonrotoclax in R/R MCL was reported at 52.4%, and the best undetectable MRD rate in blood was 49.0%. Sonrotoclax monotherapy was generally well tolerated with manageable toxicities and no clinical tumor lysis syndrome observed. Updated data are scheduled to be presented on December 8, and the results are under review by China's National Medical Products Administration for potential accelerated approval.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK0239":"医药制造"},"translate_title":"BeOne Medicines AG在ASH 2025上报告了Sonrotoclax治疗B细胞恶性肿瘤的有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9},"content_text":"BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025\n    \n\n        BeOne Medicines AG has announced new clinical data on sonrotoclax, a next-generation investigational BCL2 inhibitor, at the 67th American Society of Hematology $(ASH)$ Annual Meeting & Exposition. The results demonstrate that sonrotoclax monotherapy achieved deep and durable clinical responses in patients with relapsed or refractory mantle cell lymphoma (R/R MCL) and chronic lymphocytic leukemia (R/R CLL). In combination with BRUKINSA, sonrotoclax showed rapid achievement of minimal residual disease (MRD) negativity in treatment-naive CLL, regardless of high-risk features. The overall response rate for sonrotoclax in R/R MCL was reported at 52.4%, and the best undetectable MRD rate in blood was 49.0%. Sonrotoclax monotherapy was generally well tolerated with manageable toxicities and no clinical tumor lysis syndrome observed. Updated data are scheduled to be presented on December 8, and the results are under review by China's National Medical Products Administration for potential accelerated approval.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251207830814) on December 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589809499","isCrawlerRequest":true}